Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label pilot study of PRN1008 in pemphigus vulgaris
2015-003564-37Phase 2Completed
- Sponsor
- Principia Biopharma
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rilzabrutinib in pemphigus vulgaris (PV) (2 arms), sponsored by Principia Biopharma. Primary endpoint: Safety. Started Jan 2016; status: completed.
02
Drugs
rilzabrutinib
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on 2015-003564-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003564-37.